Agents Targeting Snat7 For Treating Cellular Metabolism Reprogramming-associated Diseases

Full-text?

The full document isn't yet available to us from the patent office.

Abstract

The present application relates to therapeutic agent reducing the expression or the activity of the SNAT7 transporter, encoded by the SLC38A7 gene or one of its variants for use in the treatment of a cellular metabolism reprogramming-associated disease, preferentially a cancer depending on glutamine, more preferentially a cancer depending on glutamine activated by one or more oncogenes selected from Ras, Myc and Src, even more preferentially a cancer depending on glutamine activated by Ras. The present invention also relates to a pharmaceutical composition comprising at least one therapeutic agent for use according to the invention, or at least one expression vector according expressing said therapeutic agent for use to the invention.


Claims

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Jan 3, 2018
  • Application: Jun 28, 2016
    EP EP 16305785 A
  • Priority: Jun 28, 2016
    EP EP 16305785 A

Download Citation


Sign in to the Lens

Feedback